We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+23.32%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.14B
AUM Growth
-$11.8M
Cap. Flow
+$77.2M
Cap. Flow %
6.76%
Top 10 Hldgs %
64.3%
Holding
85
New
15
Increased
23
Reduced
19
Closed
17

Top Buys

Rank Stock Value
1
NTRA icon
Natera
NTRA
+$51.9M
2
CTLT
CATALENT, INC.
CTLT
+$37.6M
3
SNY icon
Sanofi
SNY
+$26.7M
4
BIIB icon
Biogen
BIIB
+$21.8M
5
GSK icon
GSK
GSK
+$18.4M

Top Sells

Rank Stock Value
1
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$96.3M
2
CYH icon
Community Health Systems
CYH
+$21M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$17M
4
LNTH icon
Lantheus
LNTH
+$14.6M
5
ABMD
Abiomed Inc
ABMD
+$13M

Sector Composition

Rank Sector Weight
1 Healthcare 89.7%
2 Miscellaneous 9.48%
3 Communication Services 0.77%
4 Financials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GSK icon
1
GSK
GSK
$102B
$124M 10.84%
3,490,457
+551,387
+19% +$18.4M
HZNP
2
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$121M 10.61%
1,064,446
-205,145
-16% -$17M
NTRA icon
3
Natera
NTRA
$47B
$108M 9.45%
2,685,959
+1,260,357
+88% +$51.9M
SNY icon
4
Sanofi
SNY
$107B
$77.7M 6.8%
1,603,348
+607,313
+61% +$26.7M
GSK icon
5
CALL
GSK
GSK
$102B
$73.6M 6.44%
2,093,700
– –
UTHR icon
6
United Therapeutics
UTHR
$22.1B
$64.7M 5.67%
232,787
-22,439
-9% -$5.66M
DHR icon
7
Danaher
DHR
$152B
$43.2M 3.78%
183,380
+28
+0% +$6.49K
TEVA icon
8
Teva Pharmaceuticals
TEVA
$42.5B
$43M 3.76%
4,712,597
+649,662
+16% +$5.67M
SNDX icon
9
Syndax Pharmaceuticals
SNDX
$1.74B
$41.2M 3.61%
1,620,713
+409,279
+34% +$9.55M
BIIB icon
10
Biogen
BIIB
$32.3B
$38M 3.33%
137,348
+77,204
+128% +$21.8M
CTLT
11
DELISTED
CATALENT, INC.
CTLT
$31.1M 2.73%
+691,677
New +$37.6M
ILMN icon
12
Illumina
ILMN
$32.6B
$28.3M 2.48%
143,989
+33,991
+31% +$7.04M
CLDX icon
13
Celldex Therapeutics
CLDX
$3.07B
$24.9M 2.18%
558,774
-67,598
-11% -$2.41M
NVST icon
14
Envista
NVST
$4.36B
$21.6M 1.89%
642,405
+9,404
+1% +$322K
XBI icon
15
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$17.9M 1.57%
216,087
+116,087
+116% +$9.4M
CNC icon
16
Centene
CNC
$32B
$17.6M 1.54%
214,561
+23,253
+12% +$1.9M
HLN icon
17
Haleon
HLN
$44.5B
$15.1M 1.32%
+1,881,470
New +$12.8M
ELV icon
18
Elevance Health
ELV
$85.5B
$14.4M 1.26%
28,042
-4,998
-15% -$2.54M
ICLR icon
19
Icon
ICLR
$13.1B
$13M 1.13%
66,693
+56,481
+553% +$11.2M
AVTR icon
20
Avantor
AVTR
$9.86B
$12.7M 1.11%
600,200
+525,748
+706% +$10.9M
THC icon
21
Tenet Healthcare
THC
$21.5B
$12.4M 1.09%
+254,586
New +$11.8M
MCRB icon
22
Seres Therapeutics
MCRB
$51.3M
$12.3M 1.08%
110,050
+13,259
+14% +$1.78M
XENE icon
23
Xenon Pharmaceuticals
XENE
$5.81B
$10.9M 0.95%
275,704
+16,092
+6% +$586K
HUM icon
24
Humana
HUM
$46.3B
$10.7M 0.94%
20,911
-3,661
-15% -$1.92M
BCRX icon
25
BioCryst Pharmaceuticals
BCRX
$2.51B
$10.1M 0.89%
+880,487
New +$11M
1
2 3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q4 2022 Portfolio in Review

As of Q4 2022, Eversept Partners held 85 positions worth $1.14B, down 1% from $1.15B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Eversept Partners deployed $77.2M of net new capital in Q4 2022, opening 15 new positions and adding to 23 existing holdings. Its largest new stake was CATALENT, INC.: 691,677 shares worth $31.1M.

By sector, the portfolio is most concentrated in Healthcare at 90% of assets, up from 72% a quarter earlier, followed by Miscellaneous and Communication Services.

On the sell side, the largest reduction was Community Health Systems, an estimated $21M trimmed.

  • Eversept Partners's largest Q4 2022 buy was CATALENT, INC.: 691,677 shares worth $31.1M.
  • Eversept Partners added most to Natera in Q4 2022, an estimated $51.9M increase.
  • Eversept Partners's biggest Q4 2022 reduction was Community Health Systems, cutting an estimated $21M.
  • Eversept Partners fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q4 2022, selling an estimated $96.3M.
  • Eversept Partners's ten largest holdings make up 64% of its $1.14B portfolio in Q4 2022.
  • Eversept Partners opened 15 new positions and closed 17 in Q4 2022.
  • Eversept Partners's portfolio value fell 1% quarter-over-quarter to $1.14B.

Based on Eversept Partners's 13F filing for Q4 2022, filed 14 Feb 2023.